Information Collection
Risk Evaluation and Mitigation Strategy (REMS) Programs to Promote Appropriate Medication Use and Knowledge: Physician Experiences with REMS Programs (CDER)
IC 250492 under ICR 202205-0910-005 · OMB 0910-0847.
⚠️ Notice: This information collection may be referencing outdated material. More recent filings for OMB 0910-0847 can be found here:
Documents and Forms
Document Name Document Type |
|---|
Other-Invitation |
Other-Invitation |
Other-Consent Form |
Other-Consent Form |
Other-Survey - Ambrisentan |
Other-Survey - Ambrisentan |
Other-Survey - Bosentan |
Other-Survey - Bosentan |
Other-Survey - Clozapine |
Other-Survey - Clozapine |
Other-Survey - Isotretinoin |
Other-Survey - Isotretinoin |
Other-Survey - Lenalidomide-Pomalido |
Other-Survey - Lenalidomide-Pomalido |
Other-Survey - Sodium Oxybate |
Other-Survey - Sodium Oxybate |
Other-Reminder Letter |
Other-Reminder Letter |
Other-IRB Letter |
Other-IRB Letter |
|
IC Document |
|
IC Document |
Information Collection (IC) Details